Association between aspirin use and the prevalence of nonalcoholic fatty liver disease: A cross-sectional study from the Third National Health and Nutrition Examination Survey

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 9, 2014, Pages 1066-1073

  Shen, H ^a   Shahzad, G ^a   Jawairia, M ^a   Bostick, R M ^b   Mustacchia, P ^a  

^a NASSAU UNIVERSITY MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG USE; ECHOGRAPH; ECHOGRAPHY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONALCOHOLIC FATTY LIVER; PREVALENCE; RISK ASSESSMENT; SEX DIFFERENCE; UNITED STATES; YOUNG ADULT; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITION; PROCEDURES; RISK;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITION SURVEYS; ODDS RATIO; PREVALENCE; UNITED STATES; YOUNG ADULT;

EID: 84907979611     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12944     Document Type: Article

References (32)

1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
3. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013; 178: 38-45.
4. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006; 40(Suppl. 1): S17-29.
5. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
6. Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 2006; 87: 1-16.
7. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-6.
8. Costanzo A, Moretti F, Burgio VL, et al. Endothelial activation by angiotensin II through NFkappaB and p38 pathways: involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 2003; 195: 402-10.
9. Ristimae T, Zilmer M, Zilmer K, Kairane C, Kullisaar T, Teesalu R. Effect of low-dose aspirin on the markers of oxidative stress. Cardiovasc Drugs Ther 1999; 13: 485-90.
10. Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996; 94: 19-25.
11. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002; 196: 1025-37.
12. Raghavan RP, Laight DW, Cummings MH. Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function. Int J Clin Pract 2014; 68: 271-7.
13. Fujita K, Nozaki Y, Wada K, et al. Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease. Gut 2008; 57: 1583-91.
14. Ibrahim M, Farghaly E, Gomaa W, et al. Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. Eur J Pharmacol 2011; 659: 289-95.
15. National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-1994. Department of Health and Human Services publication No (PHS) 94-1308. Vital and health statistics. Series 1. No. 32, 1994.
16. Rolka DB, Fagot-Campagna A, Narayan KM. Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 2001; 24: 197-201.
17. Centers for Disease Control and Prevention (CDC). Cigarette smokingattributable morbidity-United States, 2000. MMWR Morb Mortal Wkly Rep 2003; 52: 842-4.
18. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factors: findings in the US population from The Third National Health and Nutrition Examination Survey, 1988- 1994. Arch Intern Med 2003; 163: 427-36.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
20. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010; 59: 1410-5.
21. Westat, Inc. Third National Health and Nutrition Examination Survey: Gallbladder Ultrasonography Procedure Manual. Rockville, MD: Westat, Inc; 1988.
22. National Center for Health Statistics. Third National Health and Nutrition Examination Survey: Hepatic Steatosis Assessment Procedure Manual. Hyattsville, MD: National Center for Health Statistics; 2010.
23. Cleanthis M, Smout J, Bhattacharya V, et al. Treadmill exercise in claudicants on aspirin results in improved antioxidant status but only minimal platelet activation. Platelets 2005; 16: 446-52.
24. Murohara T, Horowitz JR, Isner JM, et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998; 97: 99-107.
25. Sánchez de Miguel L, de Frutos T, López-Farré A, et al. Aspirin inhibits inducible nitric oxide synthase expression and tumor necrosis factoralpha release by cultured smooth muscle cells. Eur J Clin Invest 1999; 29: 93-9.
26. Campbell JS, Hughes SD, Fausto N, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 2005; 102: 3389-94.
27. Prattali RR, Barreiro GC, Carvalheira JB, et al. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in growth hormone treated animals. FEBS Lett 2005; 579: 3152-8.
28. Tarantino G, Caputi A. JNKs, insulin resistance and inflammation: a possible link between NAFLD and coronary artery disease. World J Gastroenterol 2011; 17: 3785-94.
29. Clária J, Planagumá A. Liver: the formation and actions of aspirintriggered lipoxins. Prostaglandins Leukot Essent Fatty Acids 2005; 73: 277-82.
30. Navarro SL, Saracino MR, Makar KW, et al. Determinants of aspirin metabolism in healthy men and women: effects of dietary inducers of UDPglucuronosyltransferases. J Nutrigenet Nutrigenomics 2011; 4: 110-8.
31. Greenblatt DJ, Abernethy DR, Boxenbaum HG, et al. Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. Arthritis Rheum 1986; 29: 971-80.
32. Tugendreich S, Pearson CI, Sagartz J, et al. NSAID-induced acute phase response is due to increased intestinal permeability and characterized by early and consistent alterations in hepatic gene expression. Toxicol Pathol 2006; 34: 168-79.